fazirsiran   Click here for help

GtoPdb Ligand ID: 14727

Synonyms: ADS-001 | ADS001 | ARO-AAT
Compound class: Nucleic acid
Comment: Fazirsiran (ADS-001) is a small interfering RNA (siRNA) that is designed to target the mRNA that would otherwise be translated into a mutant, misfolded and aggregating version of the AAT protein (known as Z-AAT which is transcribed from the mutant SERPINA1 PI*ZZ allele) in patients with alpha-1 antitrypsin deficiency [2-4].
To improve pharmacokinetics, the nucleotides are chemically modified (2'-O-methyl/2'-MOE and 2'-deoxy-2'-fluoro/2'-F monomers), with a mixed phosphorothioate/phosphate backbone, and it has sugar modifications at both ends of the forward strand to enhance hepatic delivery via binding to liver-expressed asialoglycoprotein receptors (ASGRs).
References
1. Liaquat T, Malik BT, Hashmi TH, Arain H, Ali MH, Haque MA. (2025)
Fazirsiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease findings from the SEQUOIA phase 2 trial.
Ann Med Surg (Lond), 87 (7): 4014-4016. [PMID:40851970]
2. Rajab I, Marin MP, Shubietah A, Khaled A, Bdair M, Abukhalil MM, Jallad H, Hussein A, Aldwaik SA, Salvatore MM. (2025)
Alpha-1 antitrypsin deficiency: genetics, clinical manifestations, AI prognostics, and advanced imaging in liver disease.
Ann Med Surg (Lond), 87 (11): 7347-7362. [PMID:41180619]
3. Strnad P, Mandorfer M, Choudhury G, Griffiths W, Trautwein C, Loomba R, Schluep T, Chang T, Yi M, Given BD et al.. (2022)
Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.
N Engl J Med, 387 (6): 514-524. [PMID:35748699]
4. Strnad P, San Martin J. (2023)
RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease.
Expert Opin Investig Drugs, 32 (7): 571-581. [PMID:37470509]